US 11,944,617 B2
Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
Hazel Hunt, Storrington (GB); and Joseph Custodio, Menlo Park, CA (US)
Assigned to Corcept Therapeutics Incorporated, Menlo Park, CA (US)
Filed by Corcept Therapeutics Incorporated, Menlo Park, CA (US)
Filed on Feb. 15, 2022, as Appl. No. 17/672,380.
Application 17/672,380 is a continuation of application No. 17/331,130, filed on May 26, 2021, granted, now 11,285,145.
Claims priority of provisional application 63/030,800, filed on May 27, 2020.
Prior Publication US 2022/0184061 A1, Jun. 16, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4725 (2006.01); A61K 31/337 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4725 (2013.01) [A61K 31/337 (2013.01); A61P 35/00 (2018.01)] 16 Claims
 
1. A method of treating cancer, comprising administering to a patient in need of treatment for said cancer:
A single agent dose of paclitaxel of between about 100 mg/m2 to about 125 mg/m2 administered without relacorilant or other anticancer pharmaceutical agents, then, about six days later,
a) a first effective dose of relacorilant; and then, one day after said administration of said single agent dose of paclitaxel,
b) an effective reduced dose of paclitaxel co-administered with a second effective dose of relacorilant, wherein said effective reduced dose of paclitaxel is reduced by an amount of between about 20% to about 35% from said single agent dose of paclitaxel when co-administered with said second effective dose of relacorilant; and
then, one day after said co-administration of said effective reduced dose of paclitaxel and said second effective dose of relacorilant,
c) a third effective dose of relacorilant, administered without paclitaxel,
effective to provide the patient with an effective level of relacorilant and an effective level of paclitaxel at the same time,
Whereby the cancer is treated.